Seres Therapeutics annual debt-to-equity ratio
2020
2021
2022
2024
2025
Seres Therapeutics Debt-to-Equity Ratio Growth & History (MCRB)
Seres Therapeutics's debt-to-equity ratio was 1.88 for fiscal 2025.
View full Seres Therapeutics company overviewSeres Therapeutics annual debt-to-equity ratio history
| Fiscal year | Period ended | Debt-to-equity ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 1.88 | −4.77 | −71.78% |
| 2024 | 2024-12-31 | 6.65 | — | — |
| 2022 | 2022-12-31 | 14.98 | 14.61 | +3952.20% |
| 2021 | 2021-12-31 | 0.37 | 0.14 | +58.83% |
| 2020 | 2020-12-31 | 0.23 | — | — |
Seres Therapeutics quarterly debt-to-equity ratio
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q2.23
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Debt-to-equity ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 1.64 | −1.01 | −38.19% |
| Q1 2026 | 2026-03-31 | 3.04 | 1.26 | +71.20% |
| Q4 2025 | 2025-12-31 | 1.88 | −4.77 | −71.78% |
| Q3 2025 | 2025-09-30 | 1.95 | −1.96 | −50.15% |
| Q2 2025 | 2025-06-30 | 2.65 | — | — |
| Q1 2025 | 2025-03-31 | 1.77 | — | — |
| Q4 2024 | 2024-12-31 | 6.65 | — | — |
| Q3 2024 | 2024-09-30 | 3.91 | — | — |
| Q2 2023 | 2023-06-30 | 9.82 | 6.50 | +195.84% |
| Q4 2022 | 2022-12-31 | 14.98 | 14.61 | +3952.20% |
| Q3 2022 | 2022-09-30 | 1.11 | 0.87 | +351.18% |
| Q2 2022 | 2022-06-30 | 3.32 | 2.88 | +654.18% |
| Q1 2022 | 2022-03-31 | 0.95 | 0.68 | +247.40% |
| Q4 2021 | 2021-12-31 | 0.37 | 0.14 | +58.83% |
| Q3 2021 | 2021-09-30 | 0.25 | 0.02 | +10.81% |
| Q2 2021 | 2021-06-30 | 0.44 | — | — |
| Q1 2021 | 2021-03-31 | 0.27 | — | — |
| Q4 2020 | 2020-12-31 | 0.23 | — | — |
| Q3 2020 | 2020-09-30 | 0.22 | — | — |
Seres Therapeutics debt-to-equity ratio trends
Over the last five fiscal years, Seres Therapeutics's debt-to-equity ratio increased from 0.23 to 1.88, a change of 1.64. The latest reported quarter, Q2 2026, shows 1.64.
About the metric
What the debt-to-equity ratio means
The debt-to-equity ratio compares interest-bearing debt with shareholders’ equity. It helps show how much debt financing a company uses relative to its accounting equity, but useful comparison levels vary by industry.
Calculation and source
How debt-to-equity is calculated
TickerStat calculates debt-to-equity as total interest-bearing debt divided by SEC-reported shareholders’ equity for the same balance-sheet date. Total liabilities are not treated as debt, and periods with non-positive equity are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Seres Therapeutics source filings ↗